Viiv Healthcare UK (No.5) Limited

Bristol-Myers Squibb Compnay

Viiv Healthcare UK Limited

Kevin M Peese

B Narasimhulu Naidu

Manoj Patel

John F Kadow

Zhongyu Wang

Michael A Walker

Timothy P Connolly

David R Langley

Chen Li

Prasanna Sivaprakasam

Stanley V D'Andrea

Margaret E Sorenson

Christiana Iwuagwu

Nicholas A Meanwell

Sanjeev Gangwar

Makonen Belema

John A Bender

Mark George Saulnier

Kyle E Parcella

Ivar M McDonald

Alan Xiangdong Wang

Kyle J Eastman

Ramkumar Rajamani

Heng Cheng

Naidu S Chowdari

Michael S Bowsher

Zhizhen Barbara Zheng

Christiana I Iwuagwu

Barry L Johnson

Tao Wang

Zhongxing Zhang

Annapurna Pendri

Zhiwei Yin

Eric P Gillis

Yasutsugu Ueda

David Bertil Frennesson

Samuel Gerritz

Francis Beaulieu

Carl Ouellet

Guo Li

Pulicharla Nagalakshmi

Weixu Zhai

Selvakumar Kumaravel

Ira B Dicker

Rongti Li

Suresh Babu

Yasutsuga Ueda

Jonathan R Weiss

Narasimhulu B Naidu

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

Inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: 

4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. 

A compound capable of inhibiting cell proliferation, having a structure according to formula (I) wherein the variables in formula (I) are as defined in the specification. Such compounds are useful as anti-cancer agents, especially in antibody-drug conjugates.

Antiproliferative compounds and conjugates made therefrom

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. 

Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication

Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. Formule (I). 

The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Growing community of inventors

Haddam, CT, United States of America

Kevin M Peese